Clinical Trial Results:
            Phase IIIb Multicenter, Single Arm, Open-label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance with Atazanavir/ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression. 
Revised Protocol 01, incorporating Protocol Amendment 01 (Version 1.0, Date 19-Jan-2007).
Estudio piloto de fase IIIb, de un solo brazo, abierto y multicéntrico, para evaluar la eficacia y la seguridad del mantenimiento con atazanavir/ritonavir en monoterapia en pacientes infectados por el VIH que muestren supresión virológica. Protocolo Revisado 01, que incorpora la enmienda 01 al protocolo (v 1.0 de fecha 19-enero-2007).
    
|     Summary | |
|     EudraCT number | 2005-005119-76 | 
|     Trial protocol | ES | 
|     Global completion date | 
                                    04 May 2009
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    24 Dec 2016
                             | 
|     First version publication date | 
                                    24 Dec 2016
                             | 
|     Other versions | |
|     Summary report(s) | AI424-227_Addendum_Synopsis AI424-227_Synopsis | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
